S-OA-G
Oral Abstracts - Session G - Allogeneic Transplants
BMT Tandem "Scientific" Meeting
Texas B (Gaylord Texan)
Chairs:
Hugo Fernandez, MD
and
Marco L. Davila, MD, PhD
Disclosures:
H. Fernandez,
Sanofi, Speakers bureau: Honoraria
M. L. Davila,
Nothing To Disclose
T-Cell Depleted Allogeneic HCT for Patients with Relapsed, High-Risk Multiple Myeloma Permits Long-Lasting Remissions in the Absence of Graft-Versus-Host Disease and Provides a Platform for Adoptive Immunotherapeutic Approaches
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Heather Landau, MD, Memorial Sloan-Kettering Cancer Center;
Hani Hassoun, MD, Memorial Sloan-Kettering Cancer Center;
Alexander M Lesokhin, MD, Memorial Sloan-Kettering Cancer Center;
Nikoletta Lendvai, MD, Memorial Sloan-Kettering Cancer Center;
David J. Chung, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Christina Bravo, MS, Memorial Sloan-Kettering Cancer Center;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center
The Australian Experience with Relapsed Acute Myeloid Leukaemia Post Allogeneic Haematopoietic Stem Cell Transplantation Yields a Simple Prognostic Index for Survival after Relapse
Andrew Boon Ming Lim, MBBS, FRACP, FRCPA, University of Melbourne;
Cameron Curley, MBBS FRACP FRCPA, Royal Brisbane & Women's Hospital;
Chun Yew Fong, MBBS FRACP FRCPA, The Alfred;
Ian Bilmon, BSc BMBS FRACP FRCPA, Westmead Hospital;
Ashanka Beligaswatte, MBBS MD, Royal Adelaide Hospital;
Duncan Purtill, MBBS, FRACP, FRCPA, Royal Perth Hospital;
Bartlomiej Getta, Westmead Hospital;
Anne Maree Johnston, Royal Prince Alfred Hospital Institute of Haematology;
Tasman Armytage, Royal North Shore Hospital;
Marnie Collins, Centre for Biostatistics and Clinical Trials;
Kate Mason, Royal Melbourne Hospital;
Katherine Fielding, MBBS, Royal Melbourne Hospital;
Matthew Greenwood, Royal North Shore Hospital;
John Gibson, Royal Prince Alfred Hospital;
Mark Hertzberg, MBBS PhD FRACP FRCPA, Westmead Hospital;
Matthew Wright, MBBS FRACP FRCPA, Royal Perth Hospital;
Ian Lewis, MBBS, PhD, Royal Adelaide Hospital;
John Moore, St. Vincent's Hospital;
David Curtis, MBBS PhD FRACP FRCPA, The Alfred;
Jeffrey Szer, MB, BS, FRACP, Royal Melbourne Hospital;
Glen Kennedy, MBBS FRACP FRCPA, Royal Brisbane & Women's Hospital;
David Stuart Ritchie, MBChB FRACP FRCPA PhD, Royal Melbourne Hospital
Delay in Onset of First Transfusion and Increased Risk of Graft Rejection in β Thalassemia Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant
Vikram Mathews, MD, Christian Medical College;
Abhijeet Ganapule, MD, Christian Medical College;
Kavitha Lakshmi, MSc, Christian Medical College;
Biju George, MD, Christian Medical College;
Aby Abraham, MD, Christian Medical College;
Auro Viswabandya, MD, Christian Medical College;
Alok Srivastava, MD, Christian Medical College
Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients
Lori Muffly, MD, MS, Colorado Blood Cancer Institute;
Masha Kocherginsky, PhD, University of Chicago;
Wendy Stock, MD, University of Chicago;
Quynh Chu, University of Chicago;
Michael R. Bishop, MD, University of Chicago;
Lucy Godley, MD, PhD, University of Chicago;
Justin Kline, MD, University of Chicago;
Hongtao Liu, MD, University of Chicago;
Olatoyosi Odenike, MD, University of Chicago;
Richard Larson, MD, University of Chicago;
Koen van Besien, MD, Cornell;
Andrew S. Artz, MD, MS, University of Chicago
Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center
Sai Ravi Pingali, MD, UT M.D. Anderson Cancer Center;
Denai Milton, The University of Texas MD Anderson Cancer Center;
Antonio di Stasi, MD, The University of Texas MD Anderson Cancer Center;
Rushang D Patel, MD, PhD, Temple University;
Partow Kebriaei, MD, UT M.D. Anderson Cancer Center;
Uday R. Popat, MD, The University of Texas MD Anderson Cancer Center;
Amin M. Alousi, MD, UT MD Anderson Cancer Center;
Paolo Anderlini, MD, The University of Texas MD Anderson Cancer Center;
Muzaffar H. Qazilbash, MD, UT M.D. Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Katy Rezvani, MD, The University of Texas MD Anderson Cancer Center;
Qaiser Bashir, MD, The University of Texas MD Anderson Cancer Center;
Betul Oran, MD, The University of Texas MD Anderson Cancer Center;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
Issa F. Khouri, MD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Stefan O. Ciurea, MD, The University of Texas MD Anderson Cancer Center
